Successful treatment of childhood prolonged refractory status epilepticus with lacosamide  by Shiloh-Malawsky, Yael et al.
Seizure 20 (2011) 586–588Case report
Successful treatment of childhood prolonged refractory status epilepticus
with lacosamide
Yael Shiloh-Malawsky *, Zheng Fan, Robert Greenwood, Michael Tennison
Department of Neurology, University of North Carolina at Chapel Hill, CB 7025, Chapel Hill, NC 27599-7025, USA
A R T I C L E I N F O
Article history:
Received 9 September 2010
Received in revised form 20 February 2011








A B S T R A C T
Prolonged, refractory status epilepticus is a rare clinical syndrome that is associated with severe
morbidity and mortality. Lacosamide is a newly approved medication for treatment of partial onset
seizures in adults, which has a novel mechanism of action. Experimental data and recent reports suggest
that lacosamide could be effective in status epilepticus. We report a child with prolonged, refractory
status epilepticus that persisted for 10 weeks despite treatment with multiple anti-epileptics and
anesthetics and was then aborted with lacosamide. This is the ﬁrst report of the effect of lacosamide in
prolonged refractory status epilepticus, and the ﬁrst report of lacosamide efﬁcacy in status epilepticus in
a child.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Status epilepticus (SE) is a life-threatening medical emergency.
It is deﬁned as ongoing seizures or repetitive seizure activity
lasting more than 30 min without recovery of consciousness
between seizures. Status epilepticus that persists despite ﬁrst and
second-line antiepileptic therapy has been deﬁned as refractory
status epilepticus (RSE) and occurs in 10–40% of SE cases.1 In a rare
subset of patients, RSE may persist for weeks or months. If status
epilepticus persists for greater than 7 days it is referred to as
prolonged, refractory status epilepticus (PRSE). Limited informa-
tion is available regarding the prognosis and management of
PRSE.2
Lacosamide is a newly approved adjunctive treatment for
partial onset epilepsy which has a novel mechanism of action that
may underlie its effectiveness in intractable epilepsy. Lacosamide’s
effect in refractory status epilepticus has not been assessed in
clinical trials.
2. Case report
An 8 year old boy with a mild learning disability was found in a
convulsive seizure after 2 days of a mild febrile illness. He was
treated with lorazepam followed by phenytoin loading and clinical
convulsions resolved but encephalopathy persisted. Initial EEG* Corresponding author. Tel.: +1 919 966 2528; fax: +1 919 966 2922.
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EEG showed frequent partial onset seizures. Treatment with
phenytoin, phenobarbital, valproic acid, and leviteracetum did not
abort the seizures. Propofol was added and titrated to induce a
burst suppression pattern but when discontinued status epilepti-
cus recurred. On the sixth day of persistent status epilepticus
pentobarbital was titrated to induce burst suppression and he was
transferred to our academic tertiary care hospital.
Examination upon presentation was signiﬁcant for a mild skin
eruption and a pleural effusion. Neurological examination showed
decreased alertness and responsiveness with no focal signs. On
presentation routine chemistries and CSF studies were normal as
were brain CT and MRI. EEG initially showed a burst suppression
pattern but when tapered off pentobarbital he had frequent,
bilaterally independent, multifocal partial onset seizures. Initially
he had subtle behavioral changes during the electrographic seizures
but subsequently had minimal behavioral accompaniment. Exten-
sive etiologic evaluation excluded traumatic, vascular, infectious,
toxic and metabolic causes of status epilepticus. Brain biopsy 3
weeks after presentation showed mild nonspeciﬁc reactive changes.
Elevated voltage gated potassium channel (VGKC) and thyroid
peroxidase antibodies and elevated CSF IgG index suggested a
potential immune etiology for the encephalopathy. Extensive
investigations failed to uncover an occult malignancy.
There was a history of mild learning disabilities that was not
formally evaluated but he had otherwise been typically developing
and had no signiﬁcant past medical or family history. There was no
recent history of exposure to medications or toxins and no history
of signiﬁcant trauma.vier Ltd. All rights reserved.
Y. Shiloh-Malawsky et al. / Seizure 20 (2011) 586–588 587Combinations of phenytoin, levetriacetam, phenobarbital,
topiramate, felbamate and valproic acid were tried over 10 weeks
without success. Propofol, pentobarbital, midazolam, and keta-
mine were employed to induce a burst suppression EEG pattern for
periods up to 1 week but SE resumed as soon as they were tapered.
Ketogenic diet was started 6 weeks after presentation but provided
no apparent beneﬁt. He was treated with high dose corticosteroids,
IVIG and plasmapheresis for a potential immune etiology.
Repeated testing for anti-VGKC antibodies after this treatment
was negative but there was no apparent clinical improvement.
Trials of vitamin B6, folinic acid, carnitine, and biotin produced no
response.
By the 10th week of PRSE he was being treated with a
combination of 6 antiepileptic agents and still having over 300
partial-onset electrographic seizures per day identiﬁed on video
EEG monitoring. At that point, 4 weeks after the last addition of a
new AED, we started treatment with enteral lacosamide 25 mg
twice daily. Within 3 days seizure frequency decreased signiﬁ-
cantly and by ﬁve days after initiation of lacomamide therapy EEG
showed complete resolution of both electrographic seizures and
interictal spikes.
After cessation of the PRSE the child showed increased alertness
and awareness and he displayed some purposeful movements but
no response to commends. Three months later he remained seizure
free and was showing improvement in attentiveness and interac-
tion but remained non-verbal and non-ambulatory.
3. Discussion
Status epilepticus may produce signiﬁcant morbidity and
mortality while RSE/PRSE is associated with an even poorer
prognosis. There are no guidelines for the management of RSE/
PRSE and few agents have been studied in prospective controlled
trials so there is limited data to guide therapy.1,3 Use of
combinations of AEDs, anesthetic agents, ketogenic diet and
surgical interventions has been described in case series.2,4 Some
authors suggest a poorer outcome with propofol use2 but in the
absence of randomized trials no agent can be considered as clearly
effective.
Lacosamide was approved in Europe and in the US in adult
patients as an adjunctive treatment of partial-onset seizures. It is a
functionalized amino acid molecule and is the only agent in clinical
use that is known to selectively promote the slow inactivation of
voltage-gatedsodium channels (VGSC).5Unlikeother anticonvulsant
drugs that affect VGSC, lacosamide has no effect on fast inactivation.6
Functional interaction with collapsin-response mediator protein 2
(CRMP2) is another unique potential mode of action of lacosamide.7
Lacosamide has a favorable pharmacokinetic proﬁle, excellent
bioavailability, minimal protein binding, few drug–drug interactions
and experimental and clinical studies suggest a favorable safety
proﬁle.5 Clinical trials in adults have demonstrated efﬁcacy in
treating partial onset epilepsy. Lacosamide has been shown to be
effective in animal models of status epilepticus and potential
neuroprotective properties have also been reported.8 Although no
clinical studies have evaluated the efﬁcacy of lacosamide in status
epilepticus, two recent cases of lacosamide use in adult patients with
status epilepticus have been published. In one case lacosamide was
effective after a ﬁrst-line drug had failed9 and in the second case after
ﬁrst and second-line anti-seizure therapies had failed.10
This child presented with pharmacoresistent PRSE, no history of
epilepsy and the etiology remains inconclusive with only a few
laboratory abnormalities. Evaluations failed to identify a cause of
the symptomatic seizures and the etiology of the mild learning
disability. He showed no dysmorphic features and both imaging
and extensive metabolic workup were normal. He was found to
have three markers of autoimmune response: elevated anti-voltage-gated potassium channel (VGKC), anti-thyroid peroxidase
antibodies and elevated CSF IgG index. VGKC autoimmunity
manifests with a wide spectrum of neurologic manifestations
including cerebral cortical manifestations such as seizures and
cognitive decline, hypothalamic, extrapyramidal, cerebellar, brain
stem, spinal cord, peripheral neuropathy, and autonomic nerve
system dysfunction.11 In patients with anti-VGKC antibodies other
organ-speciﬁc autoanbtibodies were found in 49% of the patients
including thyroid immune disorders in 21%.11 It was suggested
that anti-VGKC antibodies may not be directly responsible for all
neurologic manifestations but may be a marker for autoimmune
neurologic disease, perhaps mediated by accompanying antibodies
or cytotoxic T-lymphocytes. While seizures are common in
patients with anti-VGKC antibodies, we found no report of anti-
VGKC presenting with PRSE. Anti-thyroid peroxidase antibodies
were mildly elevated but failure to respond to steroid treatment
makes Hashimoto’s Encephalopathy unlikely.
We believe that our case has similarities to a recently proposed
clinical syndrome of childhood onset catastrophic epileptic
encephalopathy that has been reported under various names
including the most recently suggested acronym FIRES: febrile
infection responsive epileptic encephalopathies of school age.12
Children of school age with no prior seizure disorder or signiﬁcant
neurological history develop seizures and an acute encephalopathy
following a nonspeciﬁc febrile prodrome. Within several days this
progresses to prolonged, pharmacoresistant, partial onset SE.
Prognosis has been universally poor and no effective therapy has
been identiﬁed. Neuropathology shows minimal cellular inﬂam-
mation similar to the biopsy in our patient. No speciﬁc etiology has
been identiﬁed but autoantibodies have been reported in
some.13,14 It has been hypothesized that autoantibodies directly
induce neuronal excitation leading to the epileptic phenomenon.13
The autoantibodies and abnormal CSF IgG index in our patient also
suggests activation of the immune system as a potential
mechanism for his illness.
It is possible the resolution of our patient’s seizures was
unrelated to the addition of lacosamide although the total
cessation of extremely frequent seizures after such a long duration
and in close temporal relationship to the addition of the drug
makes this unlikely. It is possible that the novel anti-seizure
mechanism of lacosamide leads to a special effectiveness in PRSE.
Further studies are required to evaluate lacosamide in the pediatric
age group and to conﬁrm this observation.
Our observation adds to the clinical data on use of lacosamide in
pediatric patients and in patients with RSE or PRSE. Because of a
favorable safety proﬁle, an available intravenous preparation and
in view of the dramatic success in our case we would recommend
early consideration of lacosamide in future cases of refractory
status epilepticus.
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